

1F-608-T025

## Monoclonal Antibody to CD26 Fluorescein (FITC) conjugated (25 tests)

Clone: BA5b

**Isotype:** Mouse IgG2a

Specificity: The mouse monoclonal antibody BA5b recognizes CD26, a 110 kDa type II

membrane glycoprotein, which is a peptidase expressed on mature thymocytes, T

cells (especially activated), B cells, NK cells and macrophages.

HLDA VI; WS Code N-L078

Regulatory Status: RUO

Immunogen: A human T cell clone

Species Reactivity: Human

**Preparation:** The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC and adjusted for

direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

20 µl reagent / 100 µl of whole blood or 10° cells in a suspension.

The content of a vial (0.5 ml) is sufficient for 25 tests.

**Expiration:** See vial label

**Lot Number:** See vial label

Background: CD26, also known as dipeptidyl peptidase IV (DPP-IV), is a homodimeric cell

surface serine peptidase that degradates IFN-gamma-induced cytokines, acts as a T cell costimulatory molecule, and participates in multiple immunopathological roles in leukocyte homing and inflammation. Alterations in its peptidase activity are characteristic of malignant transformation. The enzymatic activity increases dramatically with tumour grade and severity. CD26 is expressed in various blood cell types, but also e.g. in cells that are histogenetically related to activated fibroblasts. Alterations in CD26 density have been reported on circulating monocytes and CD4+ T cells during rheumatoid arthritis and systemic lupus

erythematosus.



## PRODUCT DATA SHEET

## References:

\*Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K: In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007 Oct;66(4):451-7.

\*Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, Vanickova Z, Lisa V, Yea C, Sedo A: Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 2007 Oct;31(4):785-92.

\*Kotacková L, Baláziová E, Sedo A: Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol (Praha). 2009;55(3):77-84.

\*Dohi O, Ohtani H, Hatori M, Sato E, Hosaka M, Nagura H, Itoi E, Kokubun S: Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology. 2009 Oct;55(4):432-40.

\*Wong PT, Wong CK, Tam LS, Li EK, Chen DP, Lam CW: Decreased expression of T lymphocyte co-stimulatory molecule CD26 on invariant natural killer T cells in systemic lupus erythematosus. Immunol Invest. 2009;38(5):350-64.

\*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.